Navigation Links
WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

SHANGHAI, China, Jan. 6 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Ge Li, the Company's Chairman and Chief Executive Officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009, at 4:30 pm Pacific Standard Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Company will broadcast its presentation. The public may access the broadcast through the Investor Relations section of the Company's web site: http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: Ron_Aldridge@wuxiapptec.com

     Juliane Snowden
     Vice President of Investor Relations
     Burns McClellan
     Tel:   +1-212-213-0006
     Email: Jsnowden@burnsmc.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech 2.0: Introducing Pharmatech Oncology
2. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. WuXi PharmaTech Announces Third Quarter 2008 Results
5. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
8. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
9. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
10. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
11. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast details ... Company,s Annual and Special Meeting. The Zenith ... Thursday, December 15, 2016 at Mount Royal ... Mount Royal Gate SW, Calgary, Alberta , ... management information circular, containing the matters to be considered at ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):